TY - JOUR
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - *Pulmonary Disease, Chronic Obstructive/diagnosis/epidemiology
KW - Retrospective Studies
KW - Disease Progression
KW - Forced Expiratory Volume
KW - Risk Factors
KW - United Kingdom/epidemiology
KW - Severity of Illness Index
KW - Copd
KW - Cprd
KW - Gold a/b
KW - Uk
KW - Exacerbation
KW - risk factor
AU - K. Rothnie
AU - B. Numbere
AU - S. Gelwicks
AU - Y. Lu
AU - R. Sharma
AU - C. Compton
AU - A. Ismaila
AU - J. Quint
AD - Value Evidence and Outcomes, R&D Global Medical, GSK, London, UK.
Value Evidence and Outcomes, R&D Global Medical, GSK, Collegeville, PA, USA.
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Global Medical, GSK, London, UK.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
National Heart and Lung Institute, Imperial College London, London, UK.
AN - 38022832
BT - Int J Chron Obstruct Pulmon Dis
C2 - PMC10676117
DO - 10.2147/copd.s413947
DP - NLM
ET - 2023/11/29
LA - eng
N1 - 1178-2005
Rothnie, Kieran J
Orcid: 0000-0003-4279-1624
Numbere, Beade
Gelwicks, Steven
Lu, Yifei
Orcid: 0000-0001-8907-4898
Sharma, Raj
Compton, Chris
Orcid: 0000-0002-7564-5343
Ismaila, Afisi S
Orcid: 0000-0002-2876-8308
Quint, Jennifer K
Orcid: 0000-0003-0149-4869
Journal Article
New Zealand
Int J Chron Obstruct Pulmon Dis. 2023 Nov 21;18:2673-2685. doi: 10.2147/COPD.S413947. eCollection 2023.
PY - 2023
SN - 1176-9106 (Print)1176-9106
SP - 2673
EP - 2685
T2 - Int J Chron Obstruct Pulmon Dis
TI - Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK
VL - 18
ER -